Use of Romiplostim for Primary Immune Thrombocytopenia in Children

REFERENCES

• Rodeghiero F, Stasi R, Gernsheimer T, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393.
   PubMed Web of Science ®Google Scholar
• Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008;55:393, 420, ix.
   PubMed Web of Science ®Google Scholar
• Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol. 1988;10:330–338.
   PubMedGoogle Scholar
• Kuhne T, Buchanan GR, Zimmerman S, A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinetal Childhood ITP Study Group. J Pediatr. 2003;143:605–608.
   PubMed Web of Science ®Google Scholar
• Riesco Riesco S, Espinazo Ramos O, García Consuegra J, Púrpura. In: Manual de diagnóstico y terapéutica en pediatría. 5th ed. Madrid: Editorial Publicación de libros médicos; 2010:256–259.
   Google Scholar
• Nugent DJ. Immune thrombocytopenic purpura of childhood. Hematol Am Soc Hematol Educ Program. 2006:97–103.
   PubMedGoogle Scholar
• Murrin RJ, Murray JA. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev. 2006;20:51–60.
   PubMed Web of Science ®Google Scholar
• Kalpatthi R, Bussel JB. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr. 2008;20:8–16.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186.
   PubMed Web of Science ®Google Scholar
• Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:660–664.
   PubMed Web of Science ®Google Scholar
• Neunert CE, Buchanan GR, Imbach P, Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112:4003–4008.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Public Assessment Reports: Romiplostim Product Information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000942/WC500039537.pdf. Revised February 4, 2011. Accessed March 15, 2011.
   Google Scholar
• Scaradavou A, Woo B, Woloski BM, Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689–2700.
   PubMed Web of Science ®Google Scholar
• El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol. 2006;115:46–52.
   PubMed Web of Science ®Google Scholar
• Beck CE, Nathan PC, Parkin PC, Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147:521–527.
   PubMed Web of Science ®Google Scholar
• Blanchette V, Imbach P, Andrew M, Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707.
   PubMed Web of Science ®Google Scholar
• Parodi E, Rivetti E, Amendola G, Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144:552–558.
   PubMed Web of Science ®Google Scholar
• Bennett CM, Rogers ZR, Kinnamon DD, Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642.
   PubMed Web of Science ®Google Scholar
• Wang J, Wiley JM, Luddy R, Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–221.
   PubMed Web of Science ®Google Scholar
• Erduran E, Aslan Y, Gedik Y, Orhan F. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr. 2003;45:295–300.
   PubMed Web of Science ®Google Scholar
• Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol. 2002;24:540–544.
   PubMed Web of Science ®Google Scholar
• Carcao MD, Zipursky A, Butchart S, Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998;424:71–74.
   PubMedGoogle Scholar
• Aledort LM, Salama A, Kovaleva L, Efficacy and safety of intravenous anti-D immunoglobulin (rhophylac) in chronic immune thrombocytopenic purpura. Hematology. 2007;12:289–295.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, Nobili B, A trial of high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood. J Pediatr. 1997;130:13–16.
   PubMed Web of Science ®Google Scholar
• Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110:3526–3531.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–1899.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia (ITP). Blood. 2011;118:28–36.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Ann Hematol. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. 2011;90(11):1341–1344.
   Google Scholar
• Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev. 2011; (7):CD008235.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Aledort L, Mathias SD, Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14:90–96.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113:2161–2171. Erratum in: Blood. 2009;113:4822.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Mufti GJ, Bain BJ, Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114:3748–3756.
   PubMed Web of Science ®Google Scholar